Abituzumab
Based on 1 Customer Validation
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.38%
- CAS 番号: 1105038-73-0
- 分子量:144.58 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG2 kappa
Human
Integrin aV/ITGAV/CD51
Abituzumab (DI17E6) (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits adhesion of PCa cells to multiple extracellular matrix proteins but not collagen I[1]
Abituzumab (100 μg/mL; 12, 18 h) inhibits inhibits motility and invasion of PCa cells[1].
Abituzumab (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits the ability of PCa cells to adhere to osteoblast and bone stromal cell lines[1].
Abituzumab (100 μg/mL; 24 h) blocks integrin-mediated cell signaling in PCa cancer cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PCa cells
-
Concentration:0.01, 0.1, 1, 10, 30,100 µg/mL
-
Incubation Time:24 h
-
Result:Promoted detachment of PCa cells from vitronectin (up to approximately 20% cells detached at 100 μg/mL), osteopontin (up to approximately 10% cells detached at 100 μg/mL) and fibronectin (up to approximately 10% cells detached at 100 μg/mL) but not from collagen I.
-
Cell Line:PCa cells
-
Concentration:100 µg/mL
-
Incubation Time:12, 18 h
-
Result:Inhibited invasive ability by approximately 25 to 30% compared to vehicle, and inhibited motility by approximately 30 to 40%.
-
Cell Line:PCa, hFOB, Saos2, HS-5, HDMEC cells
-
Concentration:0.01, 0.1, 1, 10, 30,100 µg/mL
-
Incubation Time:24 h
-
Result:Inhibited PCa cells adhesion to human osteoblast cell lines hFOB and Saos2 and a bone marrow stromal cell line, HS-5.
Promoted detachment of PCa cells from to a known expressor of αv integrins, HDMEC cells.
-
Cell Line:PC3, DU145, C4-2B, LNCaP, ARCaP and VCaP cells
-
Concentration:100 µg/mL
-
Incubation Time:24 h
-
Result:Inhibited FAK phosphorylation starting at 12 h and 6 h in C4-2B and LNCaP, respectively; AKT phosphorylation starting at 3 h and 2 h in C4-2B and LNCaP, respectively; and ERK phosphorylation at starting at 1 h and 1.5 h in C4-2B and LNCaP, respectively.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Immobilized Integrin alpha V beta 3 Protein, Human (HEK293, His, solution, HY-P73868) can bind Abituzumab. The EC50 for this effect is 4.5 ng/mL. -
Flow cytometric analysis of 1X106 A549 cells with Abituzumab (HY-P99183, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 1105038-73-0
-
性状 Liquid
-
分子量 144.58 kDa
-
Color Colorless to light yellow
-
SMILES
[Abituzumab]
-
別名
EMD 525797; DI17E6
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)